1. Acknowledgement

   Acknowledgments 25 November 2012 Pages: 1169 - 1171

2. Do Pharmacogenomic Tests Provide Value to Policy Makers?

   • Ya-Chen Tina Shih
   • Lajos Pusztai

   Editorial 25 November 2012 Pages: 1173 - 1177

   

3. Letter From the Commissioner’s Office at the US FDA

   • John A. Vernon

   Editorial 25 November 2012 Pages: 1179 - 1179

4. Assessing Generalisability in Model-Based Economic Evaluation Studies

   • Hege Urdahl
   • Andrea Manca
   • Mark J. Sculpher

   Review Article 25 November 2012 Pages: 1181 - 1197

   

5. Generic Health-Related Quality-of-Life Assessment in Children and Adolescents

   • Ulrike Ravens-Sieberer
   • Michael Erhart
   • Monika Bullinger

   Review Article 25 November 2012 Pages: 1199 - 1220

   

6. Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

   • James R. Spalding
   • Joel Hay

   Original Research Article 25 November 2012 Pages: 1221 - 1232

   

7. Association of Co-Morbidities with Prescribing Patterns and Cost Savings

   • Wei Yu
   • Xinhua S. Ren
   • Lewis E. Kazis

   Original Research Article 25 November 2012 Pages: 1233 - 1248

   

8. Candesartan Cilexetil

   • Greg L. Plosker
   • Susan J. Keam

   Adis Pharmacoeconomic Drug Evaluation 25 November 2012 Pages: 1249 - 1272

   

9. Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies

   • Stuart Birks

   Correspondence 25 November 2012 Pages: 1273 - 1274

10. The Authors’ Reply

    • J. M. Bos
    • M. J. Postma
    • L. Annemans

    Correspondence 25 November 2012 Pages: 1275 - 1276